Pregled bibliografske jedinice broj: 1276083
Fulvestrant 500 mg is more effective than fulvestrant 250 mg in real-life clinical setting; Croatian prospective cohort study
Fulvestrant 500 mg is more effective than fulvestrant 250 mg in real-life clinical setting; Croatian prospective cohort study // CEOC 2016 Book of Abstracts
Opatija, Hrvatska, 2016. str. 63-63 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1276083 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Fulvestrant 500 mg is more effective than fulvestrant 250 mg in
real-life clinical setting; Croatian prospective cohort study
(Fulvestrant 500 mg is more effective than
fulvestrant 250 mg in real-life clinical setting;
Croatian prospective cohort study)
Autori
Tečić Vuger, Ana ; Pavlović, Mirjana ; Silovski, Tajana ; Šeparović, Robert ; Bajić, Žarko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
CEOC 2016 Book of Abstracts
/ - , 2016, 63-63
Skup
12th Central European Oncology Congress A Best of ASCO®
Mjesto i datum
Opatija, Hrvatska, 22.06.2016. - 25.06.2016
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Metastatic breast cancer, fulvestrant treatment
Sažetak
CONFIRM, phase III randomized controlled trial, has shown statistically significant and clinically relevant superiority of fulvestrant 500 mg over 250 mg (HR=0.80 ; 95% CI 0.68-0.94) with median PFS times of 6.5 and 5.5 months respectively. Objective of our study was to compare efficacy of two mentioned fulvestrant dosages in real - life conditions.Our study proved the superiority of fulvestrant 500 mg over fulvestrant 250 mg in real - life clinical settings.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za tumore,
Klinički bolnički centar Zagreb
Profili:
Mirjana Pavlović
(autor)
Ana Tečić Vuger
(autor)
Tajana Silovski
(autor)
Robert Šeparović
(autor)
